I am a physician-scientist experienced in clinical and translational laboratory efforts to understand and improve upon cancer immunotherapies.
Clinically, I see patients in the Cancer Immunotherapy Program where I am an attending physician, principal investigator, and co-investigator on early-phase/first-in-human trials testing novel immunotherapies in advanced solid tumors, with a particular focus on genitourinary malignancies. This includes high-risk modalities such as bispecific T cell engaging therapies, immune agonist antibodies, intratumoral immunotherapy, and adoptive cell therapies.
In the laboratory, I study samples from prostate and bladder cancer patients treated with immunotherapy using unbiased platforms such as single-cell RNA sequencing and T cell receptor sequencing. The goal of this work is to discover and validate novel T cell populations and antigenic specificities that are responsible for anti-tumor efficacy as well as immune-related adverse events (IRAEs) resulting from treatment.
March 1, 2019 - February 29, 2024 - Identification of circulating and tissue-specific autoimmune responses in checkpoint inhibitor-induced immune-related adverse events , Principal Investigator . Sponsor: NIH, Sponsor Award ID: K08AI139375
Harvard College, Cambridge, MA, AB, 06/2000, Biochemical Sciences
Stanford University School of Medicine, Stanford, CA, MD, 06/2011, Medicine
Stanford University School of Medicine, Stanford, CA, PhD, 06/2011, Molecular and Cellular Physiology
University of California, San Francisco, CA, Residency, 06/2014, Internal Medicine
University of California, San Francisco, CA, Fellowship, 06/2017, Hematology/Oncology